Cecilia Berin
Icahn School of Medicine at Mount Sinai
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cecilia Berin.
Science | 2013
Meimei Shan; Maurizio Gentile; John R. Yeiser; A. Cooper Walland; Victor Ugarte Bornstein; Kang Chen; Bing He; Linda Cassis; Anna Bigas; Montserrat Cols; Laura Comerma; Bihui Huang; J. Magarian Blander; Huabao Xiong; Lloyd Mayer; Cecilia Berin; Leonard H. Augenlicht; Anna Velcich; Andrea Cerutti
Guardian of the Gut The intestine is able to tolerate continual exposure to large amounts of commensal bacteria and foreign food antigens without triggering an inappropriate inflammatory immune response. In the large intestine, this immunological tolerance is thought to occur via a physical separation between environment and host imposed by a continuous mucous layer built up from the secreted mucin protein, MUC2. However, in the small intestine, this mucous layer is porous, necessitating an additional layer of immune control. Shan et al. (p. 447, published online 26 September; see the Perspective by Belkaid and Grainger) now report that in the small intestine, MUC2 plays an active role in immunological tolerance by activating a transcription factor in resident dendritic cells, thereby selectively blocking their ability to launch an inflammatory response. This work identifies MUC2 as a central mediator of immune tolerance to maintain homeostasis in the gut and possibly at other mucosal surfaces in the body. Mucus not only forms a physical barrier in the intestine but also promotes immunological tolerance of bacteria and foods. [Also see Perspective by Belkaid and Grainger] A dense mucus layer in the large intestine prevents inflammation by shielding the underlying epithelium from luminal bacteria and food antigens. This mucus barrier is organized around the hyperglycosylated mucin MUC2. Here we show that the small intestine has a porous mucus layer, which permitted the uptake of MUC2 by antigen-sampling dendritic cells (DCs). Glycans associated with MUC2 imprinted DCs with anti-inflammatory properties by assembling a galectin-3–Dectin-1–FcγRIIB receptor complex that activated β-catenin. This transcription factor interfered with DC expression of inflammatory but not tolerogenic cytokines by inhibiting gene transcription through nuclear factor κB. MUC2 induced additional conditioning signals in intestinal epithelial cells. Thus, mucus does not merely form a nonspecific physical barrier, but also constrains the immunogenicity of gut antigens by delivering tolerogenic signals.
Gastroenterology | 2008
Limin Shang; Masayuki Fukata; Nanthakumar Thirunarayanan; Andrea P. Martin; Paul Arnaboldi; David Maussang; Cecilia Berin; Jay C. Unkeless; Lloyd Mayer; Maria T. Abreu; Sergio A. Lira
BACKGROUND & AIMS Several lines of evidence support a role for Toll-like receptor (TLR) signaling to protect the intestine from pathogenic infection. We hypothesized that TLR signaling at the level of the intestinal epithelium is critical for mucosal immune responses. METHODS We generated transgenic mice that express a constitutively active form of TLR4 in the intestinal epithelium (V-TLR4 mice). Lamina propria cellularity was evaluated by immunostaining and flow cytometry. Immunoglobulin (Ig) A levels in the stool and serum were measured by enzyme-linked immunosorbent assay. Chemokine and cytokine expression were analyzed by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. RESULTS V-TLR4 transgenic mice reproduced normally and had a normal life span. Constitutive activity of TLR4 in the intestinal epithelium promoted recruitment of B cells and an increase in fecal IgA levels. Intestinal epithelial cells of V-TLR4 mice expressed higher levels of CCL20 and CCL28, chemokines known to be involved in B-cell recruitment, and of a proliferation-inducing ligand (APRIL), a cytokine that promotes T-cell-independent class switching of B cells to IgA. The changes in B-cell numbers and IgA levels were blocked by simultaneous expression in intestinal epithelial cells of M3, a herpes virus protein that binds and inhibits multiple chemokines. CONCLUSIONS TLR signaling in the intestinal epithelial cells significantly elevated the production of IgA in the intestine. This effect was mediated by TLR-induced expression of a specific set of chemokines and cytokines that promoted both recruitment of B cells into the lamina propria and IgA class switching of B cells.
Journal of Immunology | 2010
Jessica Melillo; Li Song; Govind Bhagat; Ana Belén Blázquez; Courtney R. Plumlee; Carolyn Lee; Cecilia Berin; Boris Reizis; Christian Schindler
Dendritic cells (DCs) must achieve a critical balance between activation and tolerance, a process influenced by cytokines and growth factors. IL-10, which transduces signals through Stat3, has emerged as one important negative regulator of DC activation. To directly examine the role Stat3 plays in regulating DC activity, the Stat3 gene was targeted for deletion with a CD11c-cre transgene. Stat3 CKO mice developed cervical lymphadenopathy as well as a mild ileocolitis that persisted throughout life and was associated with impaired weight gain. Consistent with this, Stat3-deficient DCs demonstrated enhanced immune activity, including increased cytokine production, Ag-dependent T-cell activation and resistance to IL-10–mediated suppression. These results reveal a cell-intrinsic negative regulatory role of Stat3 in DCs and link increased DC activation with perturbed immune homeostasis and chronic mucosal inflammation.
The Journal of Allergy and Clinical Immunology | 2016
Stacie M. Jones; A. Wesley Burks; Corinne A. Keet; Brian P. Vickery; Amy M. Scurlock; Robert A. Wood; Andrew H. Liu; Scott H. Sicherer; Alice K. Henning; Robert Lindblad; Peter Dawson; Cecilia Berin; David M. Fleischer; Donald Y.M. Leung; Marshall Plaut; Hugh A. Sampson
BACKGROUND We previously reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT) in which 27.5% of subjects achieved sustained unresponsiveness (SU) after 2 years. Here we report the results of treatment through 4 years and long-term follow-up. OBJECTIVE We sought to evaluate the efficacy and safety of eOIT in participants treated up to 4 years. METHODS Children with egg allergy (5-18 years old) received eOIT (n = 40) for up to 4 years or placebo (n = 15) for 1 year or less. The key outcome was the percentage of subjects achieving SU by year 4. Safety and immunologic assessments were performed, and long-term follow-up questionnaires (LFQs) were administered after study conclusion (LFQ-1) and 1 year later (LFQ-2). RESULTS Of 40 eOIT-treated subjects, 20 (50.0%) of 40 demonstrated SU by year 4. For those subjects still dosing during years 3 and 4, mild symptoms were present in 12 (54.5%) of 22 subjects. At the time of the LFQ, more subjects receiving eOIT (LFQ-1, 23/34 [68%]; LFQ-2, 21/33 [64%]) were consuming unbaked and baked egg versus placebo (LFQ-1, 2/11 [18%], P = .006; LFQ-2, 3/12 [25%], P = .04). Of subjects achieving SU, 18 (90%) of 20 completed the LFQ, with 18 (100%) of 18 reporting consumption of all forms of egg. When compared with subjects not achieving SU, subjects achieving SU had higher IgG4 values (P = .001) and lower egg skin prick test scores (P = .0002) over time and a lower median baseline ratio of egg-specific IgE to total IgE (1.1% vs 2.7%, P = .04). CONCLUSIONS SU after eOIT is enhanced with longer duration of therapy and increases the likelihood of tolerating unbaked egg in the diet.
The Journal of Allergy and Clinical Immunology | 2017
Anna Nowak-Węgrzyn; Mirna Chehade; Marion Groetch; Jonathan M. Spergel; Robert A. Wood; Katrina J. Allen; Dan Atkins; Sami L. Bahna; Ashis Barad; Cecilia Berin; Terri Brown Whitehorn; A. Wesley Burks; Jean-Christoph Roger J-P Caubet; Antonella Cianferoni; Marisa L. Conte; Carla M. Davis; Alessandro Fiocchi; Kate Grimshaw; Ruchi S. Gupta; Brittany Hofmeister; J B Hwang; Yitzhak Katz; George N. Konstantinou; Stephanie A. Leonard; Jennifer Lightdale; Sean A. McGhee; Sami Mehr; Stefano Miceli Sopo; Giovanno Monti; Antonella Muraro
&NA; Food protein–induced enterocolitis (FPIES) is a non‐IgE cell‐ mediated food allergy that can be severe and lead to shock. Despite the potential seriousness of reactions, awareness of FPIES is low; high‐quality studies providing insight into the pathophysiology, diagnosis, and management are lacking; and clinical outcomes are poorly established. This consensus document is the result of work done by an international workgroup convened through the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology and the International FPIES Association advocacy group. These are the first international evidence‐based guidelines to improve the diagnosis and management of patients with FPIES. Research on prevalence, pathophysiology, diagnostic markers, and future treatments is necessary to improve the care of patients with FPIES. These guidelines will be updated periodically as more evidence becomes available.
Clinical & Experimental Allergy | 2014
Kirsi M. Järvinen; Jennifer Westfall; Max S. Seppo; Aisha K. James; Angela Tsuang; Paul J. Feustel; Hugh A. Sampson; Cecilia Berin
The role of maternal avoidance diets in the prevention of food allergies is currently under debate. Little is known regarding the effects of such diets on human milk (HM) composition or induction of infant humoral responses.
Clinical & Experimental Allergy | 2017
Leticia Tordesillas; Nuria Cubells-Baeza; Cristina Gómez-Casado; Cecilia Berin; Vanesa Esteban; Weronika Barcik; Liam O'Mahony; Carmen Ramirez; Luis F. Pacios; María Garrido-Arandia; Araceli Díaz-Perales
Recently, the nature of the lipid‐ligand of Pru p 3, one of the most common plant food allergens in southern Europe, has been identified as a derivative of the alkaloid camptothecin bound to phytosphingosine. However, the origin of its immunological activity is still unknown.
Gastroenterology | 2007
Ping Chang Yang; Zhou Xing; Cecilia Berin; Johan D. Söderholm; Bai–Sui Feng; Linda Wu; Calvin H. Yeh
Current Allergy and Asthma Reports | 2008
Heather Lemon-Mulé; Anna Nowak-Węgrzyn; Cecilia Berin; Adina Kay Knight
The Journal of Allergy and Clinical Immunology | 2015
Leticia Tordesillas; Lucie Mondoulet; Pierre Henri Benhamou; Hugh A. Sampson; Cecilia Berin